PL378570A1 - Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowych - Google Patents

Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowych

Info

Publication number
PL378570A1
PL378570A1 PL378570A PL37857004A PL378570A1 PL 378570 A1 PL378570 A1 PL 378570A1 PL 378570 A PL378570 A PL 378570A PL 37857004 A PL37857004 A PL 37857004A PL 378570 A1 PL378570 A1 PL 378570A1
Authority
PL
Poland
Prior art keywords
polymorphs
protein kinase
kinase inhibitors
pyrrole substituted
indolinone protein
Prior art date
Application number
PL378570A
Other languages
English (en)
Inventor
Changquan Sun
Todd P. Foster
Fusen Han
Michael Hawley
Tom Thamann
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of PL378570A1 publication Critical patent/PL378570A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL378570A 2003-02-24 2004-02-23 Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowych PL378570A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44886303P 2003-02-24 2003-02-24
US10/776,337 US7452913B2 (en) 2003-02-24 2004-02-12 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (1)

Publication Number Publication Date
PL378570A1 true PL378570A1 (pl) 2006-05-02

Family

ID=32930498

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378570A PL378570A1 (pl) 2003-02-24 2004-02-23 Odmiany polimorficzne pirolo-podstawionego 2-indolinonu jako inhibitory kinaz białkowych

Country Status (14)

Country Link
US (2) US7452913B2 (pl)
EP (2) EP1599200A4 (pl)
JP (1) JP2006518755A (pl)
KR (1) KR20050107588A (pl)
AU (1) AU2004215407C1 (pl)
BR (1) BRPI0407795A (pl)
CA (1) CA2516900A1 (pl)
MX (1) MXPA05008959A (pl)
NO (1) NO20054071L (pl)
NZ (1) NZ541720A (pl)
PL (1) PL378570A1 (pl)
RU (1) RU2335502C2 (pl)
WO (1) WO2004076410A2 (pl)
ZA (1) ZA200506370B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
KR101050906B1 (ko) * 2005-09-19 2011-07-20 화이자 프로덕츠 인크. 피롤 치환된 2-인돌리논의 고체 염 형태
TWI387019B (zh) * 2007-08-02 2013-02-21 日月光半導體製造股份有限公司 在基材上形成穿導孔之方法
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2545034A1 (en) 2010-03-10 2013-01-16 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
ATE331514T1 (de) * 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US7119209B2 (en) * 2002-02-15 2006-10-10 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
WO2004076410A8 (en) 2005-10-20
JP2006518755A (ja) 2006-08-17
US20090048327A1 (en) 2009-02-19
CA2516900A1 (en) 2004-09-10
NO20054071D0 (no) 2005-09-01
AU2004215407C1 (en) 2009-07-09
WO2004076410A3 (en) 2005-03-03
NZ541720A (en) 2009-02-28
AU2004215407A1 (en) 2004-09-10
EP1599200A2 (en) 2005-11-30
HK1086486A1 (en) 2006-09-22
ZA200506370B (en) 2006-12-27
EP1599200A4 (en) 2007-02-07
KR20050107588A (ko) 2005-11-14
RU2335502C2 (ru) 2008-10-10
BRPI0407795A (pt) 2006-02-14
MXPA05008959A (es) 2005-11-04
EP2258699A1 (en) 2010-12-08
RU2005129743A (ru) 2006-02-10
US20040259929A1 (en) 2004-12-23
WO2004076410A2 (en) 2004-09-10
US7452913B2 (en) 2008-11-18
NO20054071L (no) 2005-10-13

Similar Documents

Publication Publication Date Title
AU3977001A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
PL371512A1 (pl) Związki indazolowe użyteczne jako inhibitory kinaz białkowych
IL186731A0 (en) Method of modulating stress-activated protein kinase system
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
IL186526A0 (en) Substituted amide derivatives as protein kinase inhibitors
ZA200306335B (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
PL1610780T5 (pl) Cykliczne inhibitory białkowych kinaz tyrozynowych
IL180325A0 (en) Fused heterocyclic kinase inhibitors
IL155618A0 (en) Indolylmaleimide derivatives as protein kinase c inhibitors
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
HUP0500111A3 (en) Indolinone derivatives useful as protein kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
ZA200610780B (en) Fused heterocyclic kinase inhibitors
IL176817A0 (en) Process for preparation of 1-(2s-3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxyben-zyl)quinuclidin-3-amine
EP1599200A4 (en) POLYMORPHS OF PYRROLE SUBSTITUTED PROTEIN KINASE 2-INDOLINONE COMPOUND INHIBITORS
IL175889A0 (en) Advanced indolinone based protein kinase inhibitors
HK1105596A (en) Lactam compounds useful as protein kinase inhibitors
HK1093686A (en) Advanced indolinone based protein kinase inhibitors
SI1458713T1 (sl) Uporaba derivatov indolinona kot inhibitorjev kinaz
HK1090031A (en) Heterocyclic kinase inhibitors
SI1684750T1 (sl) aminoariloksazolne spojine kot inhibitorji tirozin kinaze
HK1084659A (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)